So erreichen Sie das Zentrum
HCP-Zentrum
Das REFERET-Referenzzentrum ist Teil eines umfangreichen Netzwerks nationaler und internationaler Zusammenarbeit bei Grundlagen- und klinischen Forschungsprojekten sowie bei der Lehre und Verbreitung von Informationen zu den behandelten Krankheiten.
Bild: Poulpy
Kontakt
RÉFÉRET National Hospital of Ophthalmology of Quinze-Vingts, Paris, France
Team
Pr Isabelle Audo
Frankreich
Dr Catherine Vignal-Clermont
Frankreich
Dr Christina Zeitz
Frankreich
Pr José-Alain Sahel
Frankreich
Klinische Studien
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
A Post-Authorization, Multicenter, Multinational, Longitudinal,Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec.
A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt’s Macular Degeneration.
An Open-Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B.
Argus® II Retinal Prosthesis System: Post-Market Study
Argus® II Retinal Stimulation System Feasibility Protocol.
LIGHT4DEAF study: study of the natural history of the syndrome of usher in a cohort of patients followed longitudinally for 5 years.
Phase I/IIa Study of SAR422459 in Patients With Stargardt’s Macular Degeneration.
Prospective Natural History Study of Retinitis Pigmentosa (PHENOROD2)
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in SubjectsWith Retinitis Pigmentosa (PIONEER).
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RetinitisPigmentosa Due to Mutations in Exon 13 of the USH2A Gene (Stellar)
Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B.
Prospective study of visual function in USHER syndrome induced by MYO7A mutation and retinotosis pigmentosa.
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2-.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
Retrospective Natural History Study of Retinitis Pigmentosa.
Validation of standardized test protocols to assess the impact of visual pathologies in daily life activities.
Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation.
Design of a mobility protocol allowing to assess the impact of visual pathologies in activities of daily living for subjects with advanced visual deficits.
A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).
High resolution and high speed Multimodal Ophthalmic Imaging (IMA-MODE).
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (MADEOS).
Safety and Efficacy of Emixustat in Stargardt Disease.
High Resolution Retina Imaging (IHR)
Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Rate of Progression in USH2A Related Retinal Degeneration
A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.
An open label dose escalation clinical trial to evaluate the safety and the tolerability of gs010 (rAAV2/2-ND4) in patients with leber hereditary optic neuropathy due to mutations in the mitochondrial nadh dehydrogenase 4 gene.
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON).
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation.
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation.
Clinical and Genetic Examination of Usher Syndrome Patients’ Cohort in Europe.
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy.
Long-Term Non-Interventional Latanoprost Study
Evaluation of safety and efficacy of r-hNGF in patients with stage 2 and 3 Neurotrophic Keratitis (REPARO).
Study of CNGB1 Retinitis Pigmentosa and Allied Hereditary Disorders
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher
Global Patient Registry of Inherited Retinal Disease